Taysha Gene Therapies Inc
Research Taysha Gene Therapies Inc (TSHA) on Bullrun: market cap USD 1.78B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTSHA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.78B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 42.41M
- Free cash flow-USD 115.33M
Valuation Snapshot
latest market cap is USD 1.78B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 9.77M | -USD 109.00M | -USD 93.83M | n/a | -0.34 | USD 319.77M | USD 50.11M | USD 246.94M |
| FY2024 | USD 8.33M | -USD 89.30M | -USD 81.60M | n/a | -0.36 | USD 139.04M | USD 43.94M | USD 71.53M |
| FY2023 | USD 15.45M | -USD 111.57M | -USD 76.89M | n/a | -0.96 | USD 143.94M | USD 40.51M | USD 74.94M |
| FY2022 | USD 2.50M | -USD 166.01M | -USD 109.01M | n/a | -3.78 | USD 87.88M | USD 37.97M | USD 949.00K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.78B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.57B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 354.55M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 330.92M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 141.12M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 448.22M | n/a | n/a | n/a |
About Taysha Gene Therapies Inc
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Taysha Gene Therapies Inc's market cap?
Taysha Gene Therapies Inc's market capitalization is USD 1.78B.
What does Taysha Gene Therapies Inc do?
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system.